We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-10.26%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.22B
AUM Growth
-$279M
Cap. Flow
-$17.4M
Cap. Flow %
-1.42%
Top 10 Hldgs %
79.8%
Holding
47
New
8
Increased
5
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$11.4M
2
ONC
BeOne Medicines Ltd
ONC
+$9.35M
3
GEHC icon
GE HealthCare
GEHC
+$8.59M
4
HIMS icon
Hims & Hers Health
HIMS
+$7.43M
5
LAB icon
Standard BioTools
LAB
+$6.77M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$18.2M
2
ILMN icon
Illumina
ILMN
+$16.8M
3
EXAS
Exact Sciences
EXAS
+$12.4M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$6.41M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$1.98B
$311M 25.38%
3,507,164
– –
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$199M 16.25%
8,707,165
– –
RVMD icon
3
Revolution Medicines
RVMD
$38.8B
$131M 10.68%
3,697,933
-1,350
-0% -$54.8K
LAB icon
4
Standard BioTools
LAB
$343M
$82.2M 6.71%
76,075,636
+4,820,959
+7% +$6.77M
RNAM
5
DELISTED
Avidity Biosciences
RNAM
$60.4M 4.93%
2,045,000
– –
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.63B
$57.5M 4.7%
900,783
-172,717
-16% -$18.2M
ILMN icon
7
Illumina
ILMN
$30.2B
$47.2M 3.86%
595,000
-155,000
-21% -$16.8M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$29.1B
$32.4M 2.65%
120,000
-20,000
-14% -$5.14M
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$28.9M 2.36%
326,378
– –
BEAM icon
10
Beam Therapeutics
BEAM
$2.66B
$27.8M 2.28%
1,425,562
+175,562
+14% +$4.6M
RLAY icon
11
Relay Therapeutics
RLAY
$4.04B
$23.8M 1.95%
9,098,574
+150,000
+2% +$588K
CDXS icon
12
Codexis
CDXS
$157M
$21.8M 1.78%
8,100,000
– –
VERV
13
DELISTED
Verve Therapeutics
VERV
$18.3M 1.49%
3,995,571
– –
EXAS
14
DELISTED
Exact Sciences
EXAS
$17.5M 1.43%
405,000
-245,000
-38% -$12.4M
NGNE icon
15
Neurogene
NGNE
$657M
$15.2M 1.24%
1,295,361
– –
NTLA icon
16
Intellia Therapeutics
NTLA
$1.5B
$14.2M 1.16%
2,000,000
– –
DNLI icon
17
Denali Therapeutics
DNLI
$3.67B
$13.5M 1.1%
990,000
– –
GPCR icon
18
Structure Therapeutics
GPCR
$3.39B
$12.1M 0.99%
700,000
– –
ONC
19
BeOne Medicines Ltd
ONC
$32.3B
$10.9M 0.89%
+40,000
New +$9.35M
GH icon
20
Guardant Health
GH
$21.6B
$10.7M 0.87%
250,000
-100,000
-29% -$4.31M
MAZE
21
Maze Therapeutics
MAZE
$1.49B
$10.4M 0.85%
+946,357
New +$11.4M
TSVT
22
DELISTED
2seventy bio
TSVT
$9.88M 0.81%
2,000,000
– –
VCYT icon
23
Veracyte
VCYT
$3.6B
$8.19M 0.67%
276,308
– –
GEHC icon
24
GE HealthCare
GEHC
$31.4B
$8.07M 0.66%
+100,000
New +$8.59M
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.69B
$7.8M 0.64%
635,000
+160,000
+34% +$2.26M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Casdin Capital held 47 positions worth $1.22B, down 19% from $1.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Casdin Capital's Q1 2025 filing shows 8 new, 5 increased, 10 reduced and 3 closed positions. Its largest new stake was Maze Therapeutics: 946,357 shares worth $10.4M. The largest sale was Sarepta Therapeutics, an estimated $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Casdin Capital's largest Q1 2025 buy was Maze Therapeutics: 946,357 shares worth $10.4M.
  • Casdin Capital added most to Standard BioTools in Q1 2025, an estimated $6.77M increase.
  • Casdin Capital's biggest Q1 2025 reduction was Sarepta Therapeutics, cutting an estimated $18.2M.
  • Casdin Capital fully exited 4D Molecular Therapeutics in Q1 2025, selling an estimated $6.41M.
  • Casdin Capital's ten largest holdings make up 80% of its $1.22B portfolio in Q1 2025.
  • Casdin Capital opened 8 new positions and closed 3 in Q1 2025.
  • Casdin Capital's portfolio value fell 19% quarter-over-quarter to $1.22B.

Based on Casdin Capital's 13F filing for Q1 2025, filed 15 May 2025.